A potent, full efficacy dopamine D1
agonist which shows no agonist activity at peripheral D2
receptors or adrenoceptors at doses which cause maximal stimulation of D1
sites. The compound appears to be fully bioavailable in brain and exhibits profound antiparkinsonism effects in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license, US Patent 5,047,536
Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.
Brewster et al.
Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist.
Kholi et al.
Dihydrexidine, a novel selective high potency, full dopamine D-1 receptor agonist.
Lovenberg et al.
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.
Taylor et al.
The citations listed below are publications that use Tocris products. Selected citations for Dihydrexidine hydrochloride include:
Showing Results 1 - 3 of 3